Derazantinib(ARQ-087)
99%
- Product Code: 100266
CAS:
1234356-69-4
| Molecular Weight: | 468.57 g./mol | Molecular Formula: | C₂₉H₂₉FN₄O |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD30532770 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Derazantinib (ARQ-087) is primarily used in the treatment of certain types of cancer, particularly those involving fibroblast growth factor receptor (FGFR) genetic alterations. It is a selective FGFR inhibitor, which makes it effective in targeting cancers driven by FGFR pathway dysregulation.
One of its key applications is in the treatment of intrahepatic cholangiocarcinoma, a rare form of bile duct cancer, especially in patients with FGFR2 fusion mutations. By inhibiting FGFR signaling, Derazantinib helps to slow down tumor growth and progression in these cases.
Additionally, it is being investigated for use in other FGFR-driven cancers, such as bladder cancer, gastric cancer, and breast cancer, where FGFR abnormalities are implicated. Its ability to specifically target FGFR makes it a promising therapeutic option for precision medicine in oncology, offering potential benefits for patients with limited treatment alternatives.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White To Yellow Solid |
| Purity (%) | Solid |
| Infrared Spectrum | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿6,680.00 |
+
-
|
Derazantinib(ARQ-087)
Derazantinib (ARQ-087) is primarily used in the treatment of certain types of cancer, particularly those involving fibroblast growth factor receptor (FGFR) genetic alterations. It is a selective FGFR inhibitor, which makes it effective in targeting cancers driven by FGFR pathway dysregulation.
One of its key applications is in the treatment of intrahepatic cholangiocarcinoma, a rare form of bile duct cancer, especially in patients with FGFR2 fusion mutations. By inhibiting FGFR signaling, Derazantinib helps to slow down tumor growth and progression in these cases.
Additionally, it is being investigated for use in other FGFR-driven cancers, such as bladder cancer, gastric cancer, and breast cancer, where FGFR abnormalities are implicated. Its ability to specifically target FGFR makes it a promising therapeutic option for precision medicine in oncology, offering potential benefits for patients with limited treatment alternatives.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :